Blockade of the PD-1/PD-L1 pathway using specific antibodies has proven efficacy in immunotherapy protocols for various cancers [12,13], particularly in the treatment of metastatic triple-negative breast cancers (TNBC), which are very aggressive, with high rates of relapse and low survival rates [14,15]. This evidence concerns the gene PDCD1 and cancer.